COMMUNIQUÉ DE PRESSE

HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of Medical OncologyV...

HalioDx SAS, the immuno-oncology diagnostic company, today announced that it has entered into a Collaboration Agreement...

HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020...

• Stephane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
• Philippe Mourere joins the...

• Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of Oncology
• Consisten...

HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s investigational first-in-class...

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...

Kite to Leverage HalioDx’s Immunoscore® Solutions to Understand Tumor Microenvironment and Guide Cancer Cell Therapies...

• A 15M€ European granted consortium led by Laurence Zitvogel from Gustave Roussy in Villejuif.
• HalioDx task is to link...

HalioDx is very proud to share this great news!

• Positive results on Immunoscore® in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA...

HalioDx SAS, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that it has...

• Results from immunotherapy based clinical trials including HalioDx’s Immunoscore®_CR  and Immunosign®, will be...

• Immunoscore® is now fully reimbursed by a first Major Private Medical Insurer in the UK 

HalioDx, an immuno-oncology...

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that the company...

• 9 agreements covering 19 countries signed in 2018
• Potential of 56 000 Immunoscore® tests annually for early-stage...